Halozyme Sees 2013 Cash Burn $45-50M, Cash Balance ~$100M
Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biopharmaceutical company dedicated to developing and commercializing innovative products that advance patient care, today announced that the Company ended 2012 with a cash balance of approximately $100 million and expects 2013 net cash burn to be between $45 and $50 million. The Company also announced it secured a $30 million term loan from Oxford Finance and Silicon Valley Bank.
© 2014 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.